Manufacturer of Controlled Substances Registration: Johnson Matthey, Inc., 4593-4594 [2015-01602]
Download as PDF
<![CDATA[
4593
Federal Register / Vol. 80, No. 18 / Wednesday, January 28, 2015 / Notices
Controlled substance
Schedule
4-Anilino-N-phenethyl-4-piperidine
(8333).
Phenylacetone (8501) ..................
Cocaine (9041) .............................
Opium, raw (9600) .......................
Poppy Straw Concentrate (9670)
II
II
II
II
II
The company plans to import the
listed controlled substances for internal
use, and to manufacture bulk
intermediates for sale to its customers.
Dated: January 21, 2015.
Joseph T. Rannazzisi,
Deputy Assistant Administrator.
Therefore, pursuant to 21 U.S.C.
952(a) and 958(a), and in accordance
with 21 CFR 1301.34, the above-named
company is granted registration as an
importer of noroxymorphone (9668), a
basic class of narcotic controlled
substance listed in schedule II.
The company plans to import small
quantities of the listed controlled
substance for the National Institute on
Drug Abuse for research activities.
Dated: January 21, 2015.
Joseph T. Rannazzisi,
Deputy Assistant Administrator.
[FR Doc. 2015–01578 Filed 1–27–15; 8:45 am]
BILLING CODE 4410–09–P
[FR Doc. 2015–01587 Filed 1–27–15; 8:45 am]
BILLING CODE P
DEPARTMENT OF JUSTICE
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Drug Enforcement Administration
[Docket No. DEA–392]
[Docket No. DEA–392]
Bulk Manufacturer of Controlled
Substances Application: Rhodes
Technologies
Importer of Controlled Substances
Registration: Research Triangle
Institute
ACTION:
ACTION:
Notice of registration.
Research Triangle Institute
applied to be registered as an importer
of a certain basic class of narcotic
controlled substance. The DEA grants
Research Triangle Institute registration
as an importer of this controlled
substance.
By notice
dated April 21, 2014, and published in
the Federal Register on April 28, 2014,
79 FR 23373, Research Triangle
Institute, Kenneth S. Rehder, Ph.D.,
Hermann Building, East Institute Drive,
P.O. Box 12194, Research Triangle Park,
North Carolina 27709, applied to be
registered as an importer of a certain
basic class of narcotic controlled
substance. No comments or objections
were submitted for this notice.
The Drug Enforcement
Administration (DEA) has considered
the factors in 21 U.S.C. 823, 952(a) and
958(a) and determined that the
registration of Research Triangle
Institute to import the basic class of
controlled substance is consistent with
the public interest and with United
States obligations under international
treaties, conventions, or protocols in
effect on May 1, 1971. The DEA
investigated the company’s maintenance
of effective controls against diversion by
inspecting and testing the company’s
physical security systems, verifying the
company’s compliance with state and
local laws, and reviewing the company’s
background and history.
mstockstill on DSK4VPTVN1PROD with NOTICES
VerDate Sep<11>2014
16:41 Jan 27, 2015
Jkt 235001
Registered bulk manufacturers of
the affected basic classes, and
applicants therefore, may file written
comments on or objections to the
issuance of the proposed registration in
accordance with 21 CFR 1301.33(a) on
or before March 30, 2015.
ADDRESSES: Written comments should
be sent to: Drug Enforcement
Administration, Attention: DEA Federal
Register Representative/ODW, 8701
Morrissette Drive, Springfield, Virginia
22152. Request for hearings should be
sent to: Drug Enforcement
Administration, Attention: Hearing
Clerk/LJ, 8701 Morrissette Drive,
Springfield, Virginia 22152.
SUPPLEMENTARY INFORMATION: The
Attorney General has delegated his
authority under the Controlled
Substances Act to the Administrator of
the Drug Enforcement Administration
(DEA), 28 CFR 0.100(b). Authority to
exercise all necessary functions with
respect to the promulgation and
implementation of 21 CFR part 1301,
incident to the registration of
manufacturers, distributors, dispensers,
importers, and exporters of controlled
substances (other than final orders in
connection with suspension, denial, or
revocation of registration) has been
redelegated to the Deputy Assistant
Administrator of the DEA Office of
Diversion Control (‘‘Deputy Assistant
Administrator’’) pursuant to section 7 of
28 CFR part 0, appendix to subpart R.
In accordance with 21 CFR
1301.33(a), this is notice that on March
DATES:
SUMMARY:
SUPPLEMENTARY INFORMATION:
Notice of application.
PO 00000
Frm 00065
Fmt 4703
Sfmt 4703
13, 2014, Rhodes Technologies, 498
Washington Street, Coventry, Rhode
Island 02816, applied to be registered as
a bulk manufacturer of the following
basic classes of controlled substances:
Controlled substance
Tetrahydrocannabinols (7370) .....
Methylphenidate (1724) ................
Codeine (9050) .............................
Dihydrocodeine (9120) .................
Oxycodone (9143) ........................
Hydromorphone (9150) ................
Hydrocodone (9193) .....................
Levorphanol (9220) ......................
Morphine (9300) ...........................
Oripavine (9330) ...........................
Thebaine (9333) ...........................
Oxymorphone (9652) ...................
Noroxymorphone (9668) ..............
Tapentadol (9780) ........................
Fentanyl (9801) ............................
Schedule
I
II
II
II
II
II
II
II
II
II
II
II
II
II
II
The company plans to manufacture
the listed controlled substances in bulk
for conversion and sale to dosage form
manufacturers.
In reference to drug code 7370 the
company plans to bulk manufacture a
synthetic tetrahydrocannabinol. No
other activity for this drug code is
authorized for this registration.
Dated: January 21, 2015.
Joseph T. Rannazzisi,
Deputy Assistant Administrator.
[FR Doc. 2015–01598 Filed 1–27–15; 8:45 am]
BILLING CODE P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA–392]
Manufacturer of Controlled
Substances Registration: Johnson
Matthey, Inc.
ACTION:
Notice of registration.
Johnson Matthey, Inc. applied
to be registered as a manufacturer of
certain basic classes of controlled
substances. The DEA grants Johnson
Matthey, Inc. registration as a
manufacturer of those controlled
substances.
SUMMARY:
By notice
dated September 25, 2014, and
published in the Federal Register on
October 7, 2014, 79 FR 60498, Johnson
Matthey, Inc., Custom Pharmaceuticals
Department, 2003 Nolte Drive, West
Deptford, New Jersey 08066–1742,
applied to be registered as a
manufacturer of a certain basic class of
controlled substance. No comments or
objections were submitted to this notice.
SUPPLEMENTARY INFORMATION:
E:\FR\FM\28JAN1.SGM
28JAN1
4594
Federal Register / Vol. 80, No. 18 / Wednesday, January 28, 2015 / Notices
The Drug Enforcement
Administration (DEA) has considered
the factors in 21 U.S.C. 823(a) and
determined that the registration of
Johnson Matthey, Inc. to manufacture
the basic classes of controlled
substances is consistent with the public
interest and with United States
obligations under international treaties,
conventions, or protocols in effect on
May 1, 1971. The DEA investigated the
company’s maintenance of effective
controls against diversion by inspecting
and testing the company’s physical
security systems, verifying the
company’s compliance with state and
local laws, and reviewing the company’s
background and history.
Therefore, pursuant to 21 U.S.C.
823(a), and in accordance with 21 CFR
1301.33, the above-named company is
granted registration as a bulk
manufacturer of marihuana (7360), a
basic class of controlled substance listed
in schedule I.
In reference to drug code 7360, the
company plans to manufacture a
synthetic version cannabidiol in bulk
for sale to its customers, who are final
dosage form manufacturers. No other
activity for this drug code is authorized
for this registration.
Dated: January 21, 2015.
Joseph T. Rannazzisi,
Deputy Assistant Administrator.
[FR Doc. 2015–01602 Filed 1–27–15; 8:45 am]
BILLING CODE P
Courtney Timberlake,
Assistant Director for Budget.
This Report is being published
pursuant to section 5 of the Statutory
Pay-As-You-Go (PAYGO) Act of 2010,
Public Law 111–139, 124 Stat. 8, 2
U.S.C. 934, which requires that OMB
issue an annual PAYGO report,
including a sequestration order if
necessary, no later than 14 working days
after the end of a congressional session.
This Report describes the budgetary
effects of all PAYGO legislation and
legislation designated as an emergency
under section 4(g) of the PAYGO Act
enacted during the second session of the
113th Congress and presents the 5-year
and 10-year PAYGO scorecards
maintained by OMB. Because neither
the 5-year nor 10-year scorecard shows
a debit for the budget year, which for
purposes of this Report is fiscal year
2015,1 a sequestration order under
subsection 5(b) of the PAYGO Act, 2
U.S.C. 934(b), is not necessary.
The scorecards include no current
policy adjustments made under section
4(c) of the PAYGO Act, 2 U.S.C. 933(c),
for legislation enacted during the
second session of the 113th Congress.
The authority for current policy
adjustments expired as of December 31,
2011. For these reasons, the Report does
not contain any information about or
descriptions of any current policy
adjustments.
I. PAYGO Legislation With Budgetary
Effects
PAYGO legislation is authorizing
legislation that affects direct spending
or revenues, and appropriations
legislation that affects direct spending
in the years beyond the budget year or
affects revenues in any year.2 For a more
complete description of the Statutory
PAYGO Act, see the OMB Web site,
https://www.whitehouse.gov/omb/paygo_
description, and Chapter 9, ‘‘Budget
Concepts,’’ of the Analytical
Perspectives volume of the 2015 Budget,
https://www.whitehouse.gov/sites/
OFFICE OF MANAGEMENT AND
BUDGET
2014 Statutory Pay-As-You-Go Act
Annual Report
Office of Management and
Budget (OMB).
AGENCY:
ACTION:
https://www.whitehouse.gov/omb/paygo_
default.
Notice.
Authority: 2 U.S.C. 934
This report is being published
as required by the Statutory Pay-AsYou-Go (PAYGO) Act of 2010, 2 U.S.C.
931 et seq. The Act requires that OMB
issue (1) an annual report as specified
in 2 U.S.C. 934(a) and (2) a
sequestration order, if necessary.
mstockstill on DSK4VPTVN1PROD with NOTICES
SUMMARY:
FOR FURTHER INFORMATION CONTACT:
Patrick Locke. 202–395–3672.
This
report and additional information about
the PAYGO Act can be found at
SUPPLEMENTARY INFORMATION:
VerDate Sep<11>2014
16:41 Jan 27, 2015
Jkt 235001
1 References to years on the PAYGO scorecards
are to fiscal years.
2 Provisions in appropriations acts that affect
direct spending in the years beyond the budget year
(also known as ‘‘outyears’’) or affect revenues in any
year are considered to be budgetary effects for the
purposes of the PAYGO scorecards except if the
provisions produce outlay changes that net to zero
over the current year, budget year, and the four
subsequent years. As specified in section 3 of the
PAYGO Act, off-budget effects are not counted as
budgetary effects. Off-budget effects refer to effects
on the Social Security trust funds (Old-Age and
Survivors Insurance and Disability Insurance) and
the Postal Service.
PO 00000
Frm 00066
Fmt 4703
Sfmt 4703
default/files/omb/budget/fy2015/assets/
concepts.pdf.
The 5-year and 10-year PAYGO
scorecards for each Congressional
session begin with the balances of costs
or savings carried over from previous
sessions and then tally the costs or
savings of PAYGO laws enacted in that
session. The 5-year PAYGO scorecard
for the second session of the 113th
Congress began with balances of savings
of $9,969 million in 2015 and $814
million in 2017, but with balances of
costs of $1,066 million in 2016 and $25
million in 2018. The completed 5-year
scorecard for the session shows that
PAYGO legislation enacted during the
session was estimated to have PAYGO
budgetary effects that reduced the
deficit by an average of $626 million
each year from 2015 through 2019.3
These new savings on the scorecard
increased the balances of savings in
2015 and 2017, reduced the balance of
costs in 2016, and eliminated the
balance of costs in 2018.
The 10-year PAYGO scorecard for the
second session of the 113th Congress
began with balances of savings of $8,209
million in each year from 2015 to 2020,
savings of $1,838 million in 2021,
savings of $1,128 million in 2022, and
costs of $7 million in 2023. The
completed 10-year scorecard for the
session shows that PAYGO legislation
for the session reduced the deficit by an
average of $1,521 million each year from
2015 through 2024. These new savings
increased the balances of savings on the
10-year scorecard from 2015 through
2022 and eliminated the costs on the
scorecard for 2023.
In the second session of the 113th
Congress, 54 laws were enacted that
were determined to constitute PAYGO
legislation. Of the 54 enacted PAYGO
laws, 19 laws were estimated to have
PAYGO budgetary effects (costs or
savings) in excess of $500,000 over one
or both of the 5-year or 10-year PAYGO
windows. These were:
• Consolidated Appropriations Act,
2014, Public Law 113–76;
• Agriculture Act of 2014, Public Law
113–79;
• OPM IG Act, Public Law 113–80;
• An Act to ensure that the reduced
annual cost-of-living adjustment to the
3 As provided in section 4(d) of the PAYGO Act,
2 U.S.C. 933(d), budgetary effects on the PAYGO
scorecards are based on congressional estimates for
bills including a reference to a congressional
estimate in the Congressional Record, and for which
such a reference is indeed present in the Record.
Absent such a congressional cost estimate, OMB is
required to use its own estimate for the scorecard.
None of the bills enacted during the second session
of the 113th Congress had such a congressional
estimate and therefore OMB was required to
provide an estimate for all PAYGO laws enacted
during the session.
E:\FR\FM\28JAN1.SGM
28JAN1
]]>Agencies
[Federal Register Volume 80, Number 18 (Wednesday, January 28, 2015)]
[Notices]
[Pages 4593-4594]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2015-01602]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA-392]
Manufacturer of Controlled Substances Registration: Johnson
Matthey, Inc.
ACTION: Notice of registration.
-----------------------------------------------------------------------
SUMMARY: Johnson Matthey, Inc. applied to be registered as a
manufacturer of certain basic classes of controlled substances. The DEA
grants Johnson Matthey, Inc. registration as a manufacturer of those
controlled substances.
SUPPLEMENTARY INFORMATION: By notice dated September 25, 2014, and
published in the Federal Register on October 7, 2014, 79 FR 60498,
Johnson Matthey, Inc., Custom Pharmaceuticals Department, 2003 Nolte
Drive, West Deptford, New Jersey 08066-1742, applied to be registered
as a manufacturer of a certain basic class of controlled substance. No
comments or objections were submitted to this notice.
[[Page 4594]]
The Drug Enforcement Administration (DEA) has considered the
factors in 21 U.S.C. 823(a) and determined that the registration of
Johnson Matthey, Inc. to manufacture the basic classes of controlled
substances is consistent with the public interest and with United
States obligations under international treaties, conventions, or
protocols in effect on May 1, 1971. The DEA investigated the company's
maintenance of effective controls against diversion by inspecting and
testing the company's physical security systems, verifying the
company's compliance with state and local laws, and reviewing the
company's background and history.
Therefore, pursuant to 21 U.S.C. 823(a), and in accordance with 21
CFR 1301.33, the above-named company is granted registration as a bulk
manufacturer of marihuana (7360), a basic class of controlled substance
listed in schedule I.
In reference to drug code 7360, the company plans to manufacture a
synthetic version cannabidiol in bulk for sale to its customers, who
are final dosage form manufacturers. No other activity for this drug
code is authorized for this registration.
Dated: January 21, 2015.
Joseph T. Rannazzisi,
Deputy Assistant Administrator.
[FR Doc. 2015-01602 Filed 1-27-15; 8:45 am]
BILLING CODE P
